文献速递中医内科中药与中成药合理使用

逍遥散治疗功能性胃肠病:随机对照试验的Meta分析与试验序贯分析

Efficacy and Safety of Chinese Herbal Medicine Xiao Yao San in Functional Gastrointestinal Disorders: A meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2022-01-20

该Meta分析纳入48项随机对照试验共4403例患者,评估逍遥散(XYS)治疗功能性胃肠病(FGIDs)的疗效与安全性。结果显示,逍遥散单用或联合西药均可提高有效率,并降低症状评分、焦虑(SAS)与抑郁(SDS)评分及复发率,多数情况下安全,未观察到严重不良事件。试验序贯分析证实主要结局信息量充足。

要点

  • 逍遥散单用或联合西药可提高FGIDs治疗有效率。
  • 逍遥散可降低FGIDs患者症状评分及焦虑、抑郁评分。
  • 逍遥散可降低复发率,且多数情况下安全。

核心结论

  • 逍遥散可改善FGIDs患者症状并降低复发率,可能成为治疗FGIDs的潜在候选药物。
  • 鉴于现有研究质量有限,未来仍需更多长期、随机、双盲临床试验。

研究设计与样本

  • 采用随机效应模型或固定效应模型进行常规Meta分析,并实施试验序贯分析(TSA)。

主要发现

  • 与西药相比,逍遥散提高FGIDs有效率[RR=1.23;(95%CI,1.19-1.27);p<0.00001]。
  • 逍遥散联合西药亦提高有效率[RR=1.26;(95%CI,1.21-1.33);p<0.00001]。
  • 逍遥散降低症状评分[SMD=-1.07;(95%CI -1.42,-0.72);Z=6.03;p<0.00001]。
  • 逍遥散降低SAS评分[MD=-6.24;(95%CI -7.48,-4.99);Z=9.81;p<0.00001]和SDS评分[MD=-6.70;(95%CI -8.18,-5.21);Z=8.83;p<0.00001]。
  • 逍遥散降低复发率[MD=-6.70;(95%CI -8.18,-5.21);Z=8.83;p<0.00001],多数情况下安全,未观察到严重不良事件。

关键数值与推荐

  • FGIDs按Rome IV标准命名为肠-脑互动障碍(DGBI)。
  • 逍遥散单用对比西药的有效率RR=1.23(95%CI 1.19-1.27)。
  • 逍遥散联合西药对比西药的有效率RR=1.26(95%CI 1.21-1.33)。
  • 症状评分SMD=-1.07(95%CI -1.42,-0.72)。
  • SAS评分MD=-6.24(95%CI -7.48,-4.99),SDS评分MD=-6.70(95%CI -8.18,-5.21)。

临床怎么用

  • 对FGIDs伴焦虑抑郁状态的患者,可考虑在规范治疗基础上联合逍遥散。
  • 使用逍遥散时需关注复发率与情绪评分改善,并监测安全性。
  • 临床决策应结合患者具体情况,并认识到现有证据质量有限。

局限性

  • 现有研究质量有限,可能影响结论可靠性。
  • 仍需更多长期、随机、双盲临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Aims: Functional gastrointestinal disorders are now named disorders of gut-brain interaction (DGBI) according to the Rome IV criteria, characterized by the interaction of gastrointestinal symptoms and dysregulation of central nervous systems. Xiao-Yao-San (XYS) is effective in the treatment of gastrointestinal symptoms in China, especially in patients with concurrent mood disorders. A meta-analysis was designed to evaluate the efficacy and safety of Xiao-Yao-San for FGIDs. Methods: We searched randomized controlled trials in seven databases from their inception till November 22, 2021. Pooled analysis included therapeutic efficacy, symptom score, Self-Rating Anxiety Scale (SAS) score, Self-Rating Depression Scale (SDS) score, and the recurrence rate. Conventional meta-analysis with random-effects model or fixed-effects model and trial sequential analysis (TSA) were performed. Results: A total of 48 RCTs were eligible for inclusion (n = 4,403). Meta-analysis results showed that XYS could improve the effective rate of FGIDs compared with western drugs [RR = 1.23; (95%CI, 1.19-1.27); p < 0.00001], and XYS combined with western medicine could also improve the effective rate [RR = 1.26; (95%CI, 1.21-1.33); p < 0.00001]. In addition, XYS could reduce the symptom score [SMD = -1.07; (95%CI -1.42, -0.72); Z = 6.03; p < 0.00001], SAS score [MD = -6.24; (95%CI -7.48, -4.99); Z = 9.81; p < 0.00001] and SDS score [MD = -6.70; (95%CI -8.18, -5.21); Z = 8.83; p < 0.00001] of FGIDs patients, and reduce the recurrence rate [MD = -6.70; (95%CI -8.18, -5.21); Z = 8.83; p < 0.00001]. XYS was safe in most cases and no serious adverse events were observed in any of the included trials. TAS showed adequate "information size" for the primary outcome, and further confirmed the efficacy of XYS in the treatment of FGIDs. Conclusion: XYS could improve symptoms and reduce recurrence rates in FGIDs patients, and XYS may be a potential candidate for the treatment of FGIDs. However, due to the limited quality of current studies, more long-term, randomized, double-blinded clinical trials are needed in future studies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=284308, identifier CRD42021284308.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu Q, Shi Z, Zhang T, et al. Efficacy and Safety of Chinese Herbal Medicine Xiao Yao San in Functional Gastrointestinal Disorders: A meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol. 2022. PMID: 35126152. doi:10.3389/fphar.2021.821802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。